121 results on '"Andrews, Jane M."'
Search Results
2. Reliability of Intestinal Ultrasound for Evaluating Crohn’s Disease Activity Using Point-of-care and Central Reading
3. HLA-DP on Epithelial Cells Enables Tissue Damage by NKp44+ Natural Killer Cells in Ulcerative Colitis
4. Therapeutic Potential of the 4 Strategies to SUlfide-REduction (4-SURE) Diet in Adults with Mild to Moderately Active Ulcerative Colitis: An Open-Label Feasibility Study
5. Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
6. Integrated Psychological Care Reduces Health Care Costs at a Hospital-Based Inflammatory Bowel Disease Service
7. Efficacy of Rectal Tacrolimus for Induction Therapy in Patients With Resistant Ulcerative Proctitis
8. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection
9. A Method to Exploit the Structure of Genetic Ancestry Space to Enhance Case-Control Studies
10. Concerns and worries in people living with inflammatory bowel disease (IBD): A mixed methods study
11. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery
12. Immune derived opioidergic inhibition of viscerosensory afferents is decreased in Irritable Bowel Syndrome patients
13. Long-term Follow-up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients With Inflammatory Bowel Disease
14. Are self-administered or minimal therapist contact psychotherapies an effective treatment for irritable bowel syndrome (IBS): A systematic review
15. EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES
16. Tu1891 THE REAL-WORLD USE OF FIVE-AMINOSALICYLATE (5ASA) TREATMENT FOR ULCERATIVE COLITIS IN AUSTRALIA AND NEW ZEALAND: CROHN'S COLITIS CURE (CCC) DATA INSIGHT'S PROGRAM
17. Tu1866 ASSESSING PATIENT-PERCEIVED BURDEN OF DISEASE IN CROHN'S DISEASE: A NOVEL SCORING APPROACH IN A REAL-WORLD AUSTRALASIAN COHORT
18. Tu1865 ASSESSING PATIENT-PERCEIVED BURDEN OF DISEASE IN ULCERATIVE COLITIS: A NOVEL SCORING APPROACH IN A REAL-WORLD AUSTRALASIAN COHORT
19. Mo1834 DOSE ESCALATED VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
20. Mo1835 DOSE ESCALATED INFLIXIMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
21. Mo1833 DOSE ESCALATED USTEKINUMAB IN INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
22. Su1874 THE BURDEN OF MENTAL HEALTH DISEASE IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
23. Su1841 VARIATION IN OUTCOMES IN INFLAMMATORY BOWEL DISEASE AT TEN AUSTRALASIAN CENTRES - CROHN'S COLITIS CURE (CCC) DATA INSIGHTS PROGRAM
24. Tu1792 REAL WORLD, NATIONAL EXPERIENCE OF ESCALATED DOSING OF ADALIMUMAB IN PEOPLE WITH INFLAMMATORY BOWEL DISEASE
25. Tu1749 POST-USTEKINUMAB INDUCTION IL-12, IL-23, AND USTEKINUMAB LEVELS ARE ASSOCIATED WITH CLINICAL RESPONSE IN A MULTICENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY
26. Tu1707 CORTICOSTEROID-FREE CLINICAL REMISSION RATES WITH GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2B GALAXI 1 STUDY
27. Su1782 QUALITY, SAFETY AND EQUITY OF CARE OUTCOMES FOR INFLAMMATORY BOWEL DISEASE PATIENTS AT FOUR AUSTRALIAN TERTIARY REFERRAL CENTRES USING THE CLOUD-BASED MANAGEMENT SYSTEM CROHN'S COLITIS CARE (CCCARE) : A REAL WORLD OBSERVATIONAL STUDY
28. Su1733 BASELINE CYTOKINE LEVELS AND MICROBIOME SIGNATURES ARE ASSOCITED WITH CLINICAL RESPONSE FOLLOWING USTEKINUMAB INDUCTION IN A MULTI-CENTRE PROSPECTIVE COHORT STUDY OF CROHN'S DISEASE PATIENTS: RESULTS FROM THE AURORA STUDY
29. 888: EFFICACY AND SAFETY OF GUSELKUMAB MAINTENANCE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 48 ANALYSES FROM THE PHASE 2 GALAXI 1 STUDY
30. Sa501 ADENOMATOUS LESIONS AND RISK FACTORS FOR ADVANCED NEOPLASIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING SURVEILLANCE COLONOSCOPY
31. Fr532 THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: WEEK 12 RESULTS FROM THE PHASE 2 GALAXI 1 STUDY
32. Chapter 99 - Small Intestinal Motor and Sensory Function and Dysfunction
33. Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility
34. Tu1966 ANAESTHETIC SUPPORT TO PERFORM COLONOSCOPY: WHEN IS IT NEEDED, WHY AND CAN WE PREDICT ‘LOW VALUE' PROCEDURES?
35. Sa1913 CONSENSUS GUIDELINES FOR THE REGULATION, PRODUCTION AND USE OF FECAL MICROBIOTA TRANSPLANTATION IN CLINICAL PRACTICE
36. Sa1809 ROUTINE PSYCHOLOGICAL SCREENING IN INFLAMMATORY BOWEL DISEASE MANAGEMENT
37. Mo1774 – Healthcare Utilisation Costs May Be Reduced by Integrating Psychological Care Into IBD Management
38. Tu1807 - Genetically Distinct Signatures of Mild and Severe Ulcerative Colitis
39. Tu1020 - Crohn's Colitis Care (CCcare) - Development and Testing of a Bespoke Cloud-Based Clinical Management System for Inflammatory Bowel Disease (IBD)
40. Mo1879 - Vedolizumab(VDZ) Real World Outcomes in Ulcerative Colitis (UC)
41. Mo1800 - Psychological Care is Needed and Welcomed by Patients with Inflammatory Bowel Disease under Routine Care
42. Su1909 - Crohn's Disease Patients with at Least 1 Nod2 Mutations and Who Smoke Regularly are Four Times as Likely to Need two or more Resections
43. The role of antidepressants in the management of inflammatory bowel disease (IBD): A short report on a clinical case-note audit
44. Mo1758 - Treat to Target: Recommendations in Ulcerative Colitis (UC) in Practice: Clinician Perceptions and Potential Barriers
45. 1078 - Short Duration, Low Intensity, Pooled Fecal Microbiota Transplantation Induces Remission in Patients with Mild-Moderately Active Ulcerative Colitis: A Randomised Controlled Trial
46. Tu1792 Expression of Gut Homing Markers on TReg Differs Between IBS and Remissive IBD
47. Su1831 Identifying “At Risk” Inflammatory Bowel Disease Patients Who May Be Targeted With a New Adjuvanted Herpes Zoster Subunit Vaccine
48. Sa1395 Nexvax2®, a Peptide-Based Antigen-Specific Immunotherapy, Administered Intra-Dermally Three-Times Over 15-Days attenuates Responsiveness to Immuno-Dominant Gluten Peptides in HLA-DQ2.5+ People With Celiac Disease (CeD)
49. Sa1396 A Single Intradermal (ID) Injection of Nexvax2®, a Peptide Composition With Dominant Epitopes for Gluten-Reactive CD4+ T Cells, Activates T Cells and Triggers Acute Gastrointestinal Symptoms in HLA-DQ2.5+ People With Celiac Disease (CeD)
50. 312 The First Validated Post-Operative Endoscopic Crohns Disease Index: The POCER Index. Identification of Key Endoscopic Prognostic Factors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.